Nanomedical Diagnostics Launches New Agile Biosensor to Accelerate Label-free Drug Development

Share Article

NHS Agile biosensors provide kinetic characterization of drug compounds and biopharmaceuticals with unprecedented ease and reliability.

Agile R100 NHS Biosensor Chip for label-free kinetic binding data

Agile R100 NHS Biosensor Chip for Label-free Kinetic Binding Data

We’re meeting the pressing need in drug discovery for an easy-to-use detection technique that can sense in complex samples, enabling a large reduction in background noise and accurate, reproducible kinetic binding measurements.

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new NHS Agile biosensor chip. The new chip reduces the number of steps needed to gain kinetic binding data for a wide range of molecules, including small and large molecules, peptides, proteins, and antibodies. NHS biosensors are designed for use on the company’s Agile R100 label-free personal assay system which has an unprecedented 11-log dynamic range, making it possible to develop weakly-binding fragments into high-affinity compounds with a single platform.

“Many pharmaceutical companies have established protocols for studying molecules using standard amine-linker chemistry,” noted Nanomedical Diagnostics CEO, Ross Bundy. “However, traditional methods using these protocols require numerous steps on complicated machines that make experiments difficult to run and prone to variability. Our new NHS biosensor combined with the single-sample format Agile R100 allows researchers to leverage these tried and true techniques, but reduces the process greatly compared to prior systems. Both experiment complexity and results variability are decreased, which gives all researchers the ability to gain reliable label-free kinetic binding data for their molecules at their benchtop, on their schedule.”

Agile R100 is the first kinetic characterization platform built with proprietary Field Effect Biosensing (FEB) technology, a breakthrough electrical technique for measuring biomolecular interactions in real-time. Unlike SPR- and BLI-based assays which have a limited ability to sense in complex samples, FEB measures changes in conductance instead of mass and is unaffected by solvents or detergents that interfere with optical readings. This provides researchers access to the first truly novel label-free technique in decades.

The NHS Agile Biosensor Chip has pre-activated amine-linker chemistry that enables rapid immobilization of any molecule with a free amine group, allowing for flexible, fast kinetic characterization using a wide range of target classes. Like all Agile biosensors, the NHS chips provide up to 10 measurements with just 10 µL drops of sample, enabling entire dose-response curves to be run with one chip, increasing cost-efficiency. Agile R100’s single-sample format lets researchers apply sample directly to the sensor surface, making the platform easy to run with little training.

“The NHS biosensor chip is the second chemistry released by the company in two months,” continues Mr. Bundy. “We’re expanding the Agile R100 system menu quickly to meet the pressing need in drug discovery for an easy-to-use detection technique that can sense in complex samples, enabling a large reduction in background noise and accurate, reproducible kinetic measurements.”

About Nanomedical Diagnostics
Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay provide highly-sensitive kinetic characterization of small molecules and proteins in complex solutions from solvents and detergents to cell fractions and tissue lysate. Using just a 10 µL drop of sample, the platform is a cutting-edge orthogonal technique for drug discovery hit validation.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website